Brussels, Belgian - May 18-22, 2025
SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled validation studies of multi-cancer early detection test, breakthrough lung cancer early detection test, and blood-based pan-cancer treatment response monitoring test at EUROMEDLAB 2025.
1. Large-scale clinical validation of OncoSeek® multi-cancer early detection test
Cancer is a critical global health issue, especially in low- and middle-income countries (LMICs). SeekIn developed a CE-IVD marked blood-based test for multi-cancer early detection (MCED), named OncoSeek®. By integrating blood-based protein tumor marker (AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1) analysis with AI algorithms, OncoSeek® offers a cost-effective solution at under $25 reagent cost per test, requiring no additional equipment, infrastructure, or technical personnel. The affordability and accessibility make it more practical for the healthcare providers in LMICs.
OncoSeek® demonstrated robust performance in early detection of multiple cancers, evaluated across 15,122 participants from seven centers in three countries, utilizing four platforms and two sample types.
OncoSeek® can detect 14 common cancer types, which account for 72% of global cancer deaths, with 58.4% sensitivity, 92.0% specificity, and an overall accuracy of 70.6% in tissue of origin (TOO) prediction.
The symptomatic cohort exhibited a high sensitivity of 73.1% at 90.6% specificity, indicating OncoSeek®'s potential for early cancer diagnosis.
2. Lung cancer early detection with LungCanSeek®
SeekIn also presented its LungCanSeek® test, a blood-based, non-invasive, and cost-effective solution for lung cancer early detection. In a study of 1,814 participants (1,095 with lung cancer and 719 without cancer) from three cohorts, LungCanSeek® showed 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs). Moreover, LungCanSeek® can also predict the possible histological subtypes. With a 77.4% subtype classification accuracy, it could offer valuable guidance for subsequent diagnosis and treatment.
For lung cancer screening, SeekIn also recommends a two-step strategy: initial screening with LungCanSeek®, followed by low-dose computed tomography (LDCT) imaging for positive cases. This integrated approach leverages the strengths of both tests, reducing false positives by over 10-fold and costs by 2.5-fold compared to sole LDCT screening in high-risk populations.
3. SeekInClarity®: blood-based pan-cancer treatment response monitoring test
While traditional imaging techniques are essential for monitoring treatment efficacy, it sometimes falls short in accurately measuring tumor changes, differentiating between treatment progress and pseudo-progression, and can be subject to interpretation bias, leading to delayed treatment decisions.
SeekInClarity® offers a breakthrough in tumor treatment monitoring with a multi-omics approach that is both cost-effective and tumor-naive. This advanced assay delivers a more precise evaluation of treatment responses, minimizes the risk of misjudgment, and speeds up the assessment process. By offering timely and objective data, SeekInClarity® empowers clinicians with the information they need to make informed, swift decisions.
In a prospective study of 116 lymphoma patients, SeekInClarity® was compared with imaging assessments to evaluate treatment effects:
The study revealed that at baseline, 74.1% of lymphoma patients had a positive MTB (molecular tumor burden) (MTB ≥ 2), with a specificity of up to 95.2%.
Survival analysis further revealed that MTB-positive patients had significantly shorter progression-free survival (PFS) compared with MTB-negative patients, both at baseline and after 2 cycles of treatment.
After two cycles of treatment, patients with MTB-positive status were more than 5.2 times more likely to develop disease progression (PD) than MTB-negative patients, outperforming existing clinical biomarkers lactate dehydrogenase (LDH) and β2-microglobulin (B2M).
About EUROMEDLAB 2025
This 26th IFCC-EFLM EuroMedLab Congress (EuroMedLab 2025), held in collaboration with the Belgian Royal Society of Laboratory Medicine and MZ Events, promises an outstanding scientific and educational experience.
EuroMedLab 2025 offers a unique opportunity to explore the latest developments in diagnostics, data science, and digital health. But it is also a place for exchange — between generations, specialities, and institutions — working toward a common goal: improving health outcomes through scientific excellence and professional engagement.